KR101487919B1 - 설사 우세형 과민성 대장 증후군을 치료하는 방법 - Google Patents

설사 우세형 과민성 대장 증후군을 치료하는 방법 Download PDF

Info

Publication number
KR101487919B1
KR101487919B1 KR20137013965A KR20137013965A KR101487919B1 KR 101487919 B1 KR101487919 B1 KR 101487919B1 KR 20137013965 A KR20137013965 A KR 20137013965A KR 20137013965 A KR20137013965 A KR 20137013965A KR 101487919 B1 KR101487919 B1 KR 101487919B1
Authority
KR
South Korea
Prior art keywords
diarrhea
bowel syndrome
irritable bowel
ibs
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR20137013965A
Other languages
English (en)
Korean (ko)
Other versions
KR20130063552A (ko
Inventor
배리 쿼트
데이비드 로젠바움
토마스 니난
로버트 블랭스
Original Assignee
나포 팔마큐티칼스 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38648619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101487919(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 나포 팔마큐티칼스 인코퍼레이션 filed Critical 나포 팔마큐티칼스 인코퍼레이션
Publication of KR20130063552A publication Critical patent/KR20130063552A/ko
Application granted granted Critical
Publication of KR101487919B1 publication Critical patent/KR101487919B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR20137013965A 2006-05-01 2007-04-30 설사 우세형 과민성 대장 증후군을 치료하는 방법 Active KR101487919B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79707406P 2006-05-01 2006-05-01
US60/797,074 2006-05-01
US11/510,152 2006-08-24
US11/510,152 US20070254050A1 (en) 2006-05-01 2006-08-24 Method for treatment of diarrhea-predominant irritable bowel syndrome
PCT/US2007/067725 WO2007130882A2 (en) 2006-05-01 2007-04-30 Method for treatment of diarrhea-predominant irritable bowel syndrome

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087029446A Division KR101537361B1 (ko) 2006-05-01 2007-04-30 설사 우세형 과민성 대장 증후군을 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20130063552A KR20130063552A (ko) 2013-06-14
KR101487919B1 true KR101487919B1 (ko) 2015-02-03

Family

ID=38648619

Family Applications (2)

Application Number Title Priority Date Filing Date
KR20137013965A Active KR101487919B1 (ko) 2006-05-01 2007-04-30 설사 우세형 과민성 대장 증후군을 치료하는 방법
KR1020087029446A Active KR101537361B1 (ko) 2006-05-01 2007-04-30 설사 우세형 과민성 대장 증후군을 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087029446A Active KR101537361B1 (ko) 2006-05-01 2007-04-30 설사 우세형 과민성 대장 증후군을 치료하는 방법

Country Status (18)

Country Link
US (3) US20070254050A1 (enExample)
EP (1) EP2034844B1 (enExample)
JP (2) JP5384329B2 (enExample)
KR (2) KR101487919B1 (enExample)
AR (1) AR060829A1 (enExample)
AU (1) AU2007248172B2 (enExample)
CA (1) CA2650294C (enExample)
DK (1) DK2034844T3 (enExample)
ES (1) ES2628290T3 (enExample)
MX (2) MX2008013871A (enExample)
NZ (2) NZ595749A (enExample)
PE (1) PE20081569A1 (enExample)
PL (1) PL2034844T3 (enExample)
PT (1) PT2034844T (enExample)
SG (1) SG174025A1 (enExample)
TR (1) TR201708043T4 (enExample)
TW (2) TWI481410B (enExample)
WO (1) WO2007130882A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
NZ572049A (en) 2006-05-01 2012-08-31 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
PT2529626T (pt) 2006-05-01 2018-02-27 Napo Pharmaceuticals Inc Composições e métodos para tratamento ou prevenção do cancro do cólon
FR2900823B1 (fr) * 2006-05-15 2009-02-13 Bioprojet Soc Civ Ile Nouvelle forme d'administration du racecadotril.
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US20110263478A1 (en) * 2008-09-16 2011-10-27 Simard J Marc Sur1 inhibitors for therapy
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
AU2010303577B2 (en) * 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
WO2011073950A1 (en) * 2009-12-17 2011-06-23 National University Of Singapore Method of preparing derivatives/oligomers of epicatechin and applications thereof
WO2012058664A1 (en) * 2010-10-31 2012-05-03 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
WO2012135702A1 (en) 2011-04-01 2012-10-04 Ocean Spray Cranberries, Inc. Inflammation and immunity treatments
US20140057993A1 (en) * 2011-04-27 2014-02-27 Northshore University Healthsystem Prophylaxis and Treatment of Enteropathogenic Bacterial Infection
WO2013161973A1 (en) * 2012-04-23 2013-10-31 Sucampo Ag Method for treating irritable bowel syndrome with diarrhea
EP2922557B1 (en) 2012-11-21 2017-10-04 KBS Research, LLC Herbal supplements and methods of use thereof
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
KR101579688B1 (ko) 2014-07-08 2015-12-24 재단법인 전남생물산업진흥원 좁쌀풀 추출물을 유효성분으로 함유하는 과민성 대장증후군에 의한 내장 통증 억제예방 또는 치료용 약학 조성물
CN104873485B (zh) * 2015-05-08 2019-02-19 中国药科大学 槲皮素治疗与胃肠道应激失调相关疾病的用途
CN107125440A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂肠溶包衣单宁酸及其制备方法以及一种饲料
IT201600122310A1 (it) 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
US20180185356A1 (en) 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea
EP3592333B1 (en) * 2017-03-06 2024-04-03 Athena Pharmaceutiques SAS A pharmaceutical composition comprising racecadotril and process for preparing the same
AU2018275685B2 (en) 2017-05-31 2025-04-17 Napo Pharmaceuticals, Inc. Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
JP2020525407A (ja) * 2017-05-31 2020-08-27 ナポ ファーマシューティカルズ インク．Ｎａｐｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 先天性下痢障害を治療するための方法及び組成物
KR20220046544A (ko) * 2019-06-12 2022-04-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 답즙산 설사를 치료하는 방법
CN113975412B (zh) * 2021-12-30 2022-04-05 北京赛尔富森生物科技有限公司 一种评价轮状病毒疫苗有效性的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
EP0214317B1 (fr) 1985-08-30 1988-08-17 Societe Des Produits Nestle S.A. Produit diététique à activité dépurative et anti-diarrhéique et son procédé de préparation
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
FI962667A7 (fi) 1996-06-27 1997-12-28 Oy Scanwoven Ab Kuitutuote, menetelmä ja laitteisto kuitutuotteen valmistamiseksi
JP4195728B2 (ja) 1996-10-16 2008-12-10 ナポ ファーマシューティカルズ，インコーポレーテッド プロアントシアニジンポリマー止瀉組成物の腸溶製剤
AU6967198A (en) 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7208183B2 (en) * 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
PT2529626T (pt) 2006-05-01 2018-02-27 Napo Pharmaceuticals Inc Composições e métodos para tratamento ou prevenção do cancro do cólon
NZ572049A (en) * 2006-05-01 2012-08-31 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
AU2010303577B2 (en) 2009-10-06 2015-10-22 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
WO2012058664A1 (en) 2010-10-31 2012-05-03 Salix Pharmaceuticals, Ltd. Methods and compositions for treating hiv-associated diarrhea
JP2016505561A (ja) 2012-12-07 2016-02-25 サリックス ファーマスーティカルズ，リミテッド Ｈｉｖ関連下痢を治療する方法および組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047062A2 (en) * 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same

Also Published As

Publication number Publication date
DK2034844T3 (en) 2017-06-06
TWI481410B (zh) 2015-04-21
TW200810772A (en) 2008-03-01
TWI574694B (zh) 2017-03-21
AU2007248172A1 (en) 2007-11-15
NZ595749A (en) 2013-11-29
PE20081569A1 (es) 2009-01-14
EP2034844A2 (en) 2009-03-18
PT2034844T (pt) 2017-06-26
WO2007130882A2 (en) 2007-11-15
TW201434475A (zh) 2014-09-16
US9980938B2 (en) 2018-05-29
PL2034844T3 (pl) 2017-09-29
EP2034844B1 (en) 2017-03-22
AR060829A1 (es) 2008-07-16
MX2008013871A (es) 2009-01-07
SG174025A1 (en) 2011-09-29
WO2007130882A3 (en) 2008-02-07
AU2007248172B2 (en) 2013-03-21
TR201708043T4 (tr) 2018-11-21
JP5820440B2 (ja) 2015-11-24
US20070254050A1 (en) 2007-11-01
KR101537361B1 (ko) 2015-07-17
CA2650294C (en) 2019-01-22
MX382400B (es) 2025-03-13
KR20090009291A (ko) 2009-01-22
JP2014012695A (ja) 2014-01-23
KR20130063552A (ko) 2013-06-14
US20120189720A1 (en) 2012-07-26
JP2009535417A (ja) 2009-10-01
US8846113B2 (en) 2014-09-30
NZ609344A (en) 2014-08-29
US20150050338A1 (en) 2015-02-19
CA2650294A1 (en) 2007-11-15
ES2628290T3 (es) 2017-08-02
EP2034844A4 (en) 2010-11-17
JP5384329B2 (ja) 2014-01-08

Similar Documents

Publication Publication Date Title
KR101537361B1 (ko) 설사 우세형 과민성 대장 증후군을 치료하는 방법
AU2007248182B2 (en) Method for treatment of constipation-predominant irritable bowel syndrome
AU2013205344B2 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
HK1128861A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
HK1128861B (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
AU2013203794A1 (en) Method for treatment of constipation-predominant irritable bowel syndrome
HK1143541B (en) Method for treatment of constipation-predominant irritable bowel syndrome

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180104

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190123

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 12